15 unknown, 10 terminated, 8 active not recruiting, 8 recruiting. 55 Phase 3, 17 Phase 2.
Follow Cholangiocarcinoma: new trials by email Literature Review of Cholangiocarcinoma trials Research Report on Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Not yet recruiting | UNICANCER | 990 | 2027-01-02 | 2026-08-04 |
| Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 3 | Not yet recruiting | Zhai Wenlong | 90 | 2026-11-30 | 2026-11-04 |
| Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma Gemcitabine, Cisplatin, Tislelizumab - Intrahepatic Cholangiocarcinoma (Icc) | Phase 3 | Not yet recruiting | Zhejiang Cancer Hospital | 140 | 2026-09-01 | 2026-10-26 |
| D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer D07001-Softgel Capsules, Placebo, Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | InnoPharmax Inc. | 240 | 2026-06-09 | 2026-11-04 |
| Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations Becotatug Vedotin, Pucotenlimab, Gemcitabine - Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | Sir Run Run Shaw Hospital | 164 | 2026-05-20 | 2026-05-20 |
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer Nanvuranlat, Physician's Best Choice - Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | J-Pharma Co., Ltd. | 480 | 2026-05-11 | 2026-09-29 |
| Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma Pembrolizumab, Gemcitabine, Cisplatin - Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma | Phase 2 / Phase 3 | Recruiting | Amsterdam UMC, location VUmc | 150 | 2026-04-17 | 2026-08-25 |
| Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations TT-00420 (tinengotinib), Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabine - Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma | Phase 3 | Not yet recruiting | TransThera Sciences (Nanjing), Inc. | 138 | 2026-01-01 | 2026-01-09 |
| Trop2-targeted immunoPET Imaging of Solid Tumors [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma | Phase 2 / Phase 3 | Recruiting | RenJi Hospital | 400 | 2024-12-23 | 2026-05-29 |
| The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma [18F]F-FAPI PET-CT - Cholangiocarcinoma | Phase 2 / Phase 3 | Recruiting | Mara Veenstra, MD | 81 | 2024-11-29 | 2025-04-11 |
| Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. futibatinib, futibatinib, fulvestrant - Advanced/Metastatic Cancer | Phase 2 / Phase 3 | Active not recruiting | Taiho Oncology, Inc. | 15 | 2024-10-01 | 2026-07-28 |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Zanidatamab, Cisplatin, Gemcitabine - Biliary Tract Cancer | Phase 3 | Recruiting | Jazz Pharmaceuticals | 286 | 2024-07-19 | 2026-11-19 |
| Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice - Cholangiocarcinoma | Phase 3 | Active not recruiting | TransThera Sciences (Nanjing), Inc. | 200 | 2023-12-20 | 2026-07-06 |
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) Rilvegostomig, Placebo, Capecitabine - Biliary Tract Cancer | Phase 3 | Active not recruiting | AstraZeneca | 760 | 2023-12-04 | 2026-10-16 |
| CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence Gemcitabine, Nab paclitaxel, Cisplatin - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Recruiting | Gruppo Oncologico del Nord-Ovest | 300 | 2023-11-07 | 2026-09-09 |
| Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study Toripalimab, Lenvatinib mesylate capsules, Placebo IV - Intrahepatic Cholangiocarcinoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 480 | 2023-06-19 | 2025-04-23 |
| An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma Ivosidenib Oral Tablet - Cholangiocarcinoma | Phase 3 | Active not recruiting | Servier Affaires Médicales | 299 | 2023-05-03 | 2026-07-31 |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) CTX-009, Paclitaxel - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Compass Therapeutics | 168 | 2023-01-09 | 2026-11-10 |
| Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer SMT-NK inj.+Pembrolizumab, Pembrolizumab - Biliary Tract Cancer | Phase 2 / Phase 3 | Unknown | SMT bio Co., Ltd. | 128 | 2022-06-09 | 2022-09-27 |
Showing 20 of 55. Sign in to see all of them.
Gallbladder Neoplasms (14) · Biliary Tract Neoplasms (13) · Bile Duct Neoplasms (7) · Klatskin Tumor (4) · Neoplasms (4) · Adenocarcinoma (2) · Carcinoma, Hepatocellular (2) · Cirrhosis, Familial, with Pulmonary Hypertension (2) · Liver Neoplasms (2) · Neoplasm Metastasis (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Urinary Bladder Neoplasms (2) · Uterine Cervical Neoplasms (2) · Anus Neoplasms (1)
Neoplasms by Histologic Type (55) · Neoplasms, Glandular and Epithelial (55) · Carcinoma (54) · Adenocarcinoma (53) · Neoplasms (51) · Digestive System Diseases (25) · Neoplasms by Site (25) · Digestive System Neoplasms (24) · Biliary Tract Diseases (22) · Gallbladder Diseases (14) · Biliary Tract Neoplasms (9) · Bile Duct Diseases (7) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Liver Diseases (3)
Gemcitabine (25) · Cisplatin (20) · Capecitabine (10) · Oxaliplatin (9) · pembrolizumab (7) · Fluorouracil (6) · Leucovorin (6) · Photochemotherapy (5) · Irinotecan (3) · ivosidenib (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Albumin-Bound Paclitaxel (2) · Cholangiopancreatography, Endoscopic Retrograde (2) · Drug Therapy (2) · Neoadjuvant Therapy (2)
Merck Sharp & Dohme LLC (2) · Shanghai Zhongshan Hospital (2) · Shi Ming (2) · TransThera Sciences (Nanjing), Inc. (2) · Weill Medical College of Cornell University (2) · Air Force Military Medical University, China (1) · Amsterdam UMC, location VUmc (1) · Asan Medical Center (1) · AstraZeneca (1) · Changhai Hospital (1) · Compass Therapeutics (1) · Concordia Laboratories Inc. (1) · Dan Zandberg (1) · Delcath Systems Inc. (1) · ECOG-ACRIN Cancer Research Group (1)
China (23) · United States (23) · United Kingdom (15) · France (14) · Italy (14) · South Korea (14) · Spain (13) · Germany (12) · Canada (10) · Belgium (9) · Australia (8) · Netherlands (8) · Taiwan (8) · Japan (6) · Austria (4)
Michel Kahaleh, MD (3) · Afshin Dowlati, MD (1) · Changping Wu, M.D. (1) · Criss Cheng (1) · Cynthia Sirard, MD (1) · Dan Zandberg, MD (1) · Deirdre J Cohen (1) · Do Hyun Park, MD, PhD (1) · Eric K Rowinsky, MD (1) · Gaojun Teng, MD (1) · Ghassan Abou-Alfa, MD (1) · Guohong Han, MD,Ph.D (1) · Harpreet Wasan, MD (1)
PMID 40812353, PMID 42176183, PMID 15691639, PMID 20165987, PMID 20375404, PMID 23703448, PMID 24485665, PMID 25456367, PMID 26228433, PMID 26503201, PMID 30785198, PMID 30914290, PMID 30998813, PMID 32374623, PMID 32461347, PMID 32580579, PMID 32677452, PMID 33798493, PMID 34515993, PMID 34554208, PMID 35935821, PMID 37075781, PMID 37368098, PMID 38278871, PMID 38589856, PMID 38661512, PMID 38689424, PMID 38861293, PMID 38875119, PMID 39206260, PMID 39671534, PMID 39978598, PMID 40154623, PMID 40268484, PMID 41469668, PMID 41646284, PMID 41780001, PMID 42223137, PMID 8708722
2019 (3), 2023 (3), 2018 (2), 2025 (1), U10CA180820 (1), U10CA180868 (1), U10CA180888 (1)